Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eli Lilly and Company
Age
40–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Have osteoarthritis (OA) of the knee joint based on American College of Rheumatology (ACR) criteria and confirmed with X-rays and ACR functional class of I to III
Have been on stable dose of prescription Nonsteroidal Anti-Inflammatory Drugs (NSAIDS), celecoxib, tramadol, or acetaminophen of at least 2000 mg per day for at least 20 days in the past month
Willing to stop all analgesics for OA pain during the study
Experienced pain while walking in the target knee of 50-90 mm inclusive on 0-100 Visual Analog Scale (VAS) with an increase in pain while walking of at least 10 mm following washout of current Osteoarthritis pain medications at screening
You may not be if
Allergic to LY2951742, celecoxib, other NSAIDS, including aspirin, and similar drugs
Arthritis of the knee from other causes
Uncontrolled hypertension
Have OA pain that requires treatment with potent opioids, systemic corticosteroids, intra-articular injections, duloxetine, or venlafaxine
Moderate to severe renal impairment
Pregnant or lactating
Clareo Health | A Study of LY2951742 in Participants With Mild to Moderate Osteoarthritis Knee Pain
